American Cancer Society Journals shared a post on LinkedIn:
“New in CA: A Cancer Journal for Clinicians | Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness.
In this editorial, Drs. Susana Campos, Jessica Buck DiSilvestro, and Stephanie Blank comment on results of the FZOCUS-1 trial testing a PARPi, fuzuloparib, with a VEGFi, apatinib, as maintenance treatment after 1st-line therapy in Ovarian Cancer.
“Although this trial could appear to settle the question of whether there is a benefit to combining a PARPI and a VEGFi as maintenance treatment, a further critical look is necessary.”
Title: Maintenance therapy after first-line therapy for ovarian cancer: Quantitative effectiveness
Authors: Susana M. Campos MD, MPH, Jessica DiSilvestro MD, Stephanie V. Blank MD
More from American Cancer Society Journals on OncoDaily.
